 T-Lymphocytes
"T-Lymphocytes" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Lymphocytes responsible for cell-mediated immunity. Two types have been identified - cytotoxic (T-LYMPHOCYTES, CYTOTOXIC) and helper T-lymphocytes (T-LYMPHOCYTES, HELPER-INDUCER). They are formed when lymphocytes circulate through the THYMUS GLAND and differentiate to thymocytes. When exposed to an antigen, they divide rapidly and produce large numbers of new T cells sensitized to that antigen.
| Descriptor ID |
D013601
|
| MeSH Number(s) |
A11.118.637.555.567.569 A15.145.229.637.555.567.569 A15.382.490.555.567.569
|
| Concept/Terms |
T-Lymphocytes- T-Lymphocytes
- T Lymphocytes
- T-Lymphocyte
- T-Cells
- T Cells
- T-Cell
- Thymus-Dependent Lymphocytes
- Lymphocyte, Thymus-Dependent
- Lymphocytes, Thymus-Dependent
- Thymus Dependent Lymphocytes
- Thymus-Dependent Lymphocyte
|
Below are MeSH descriptors whose meaning is more general than "T-Lymphocytes".
Below are MeSH descriptors whose meaning is more specific than "T-Lymphocytes".
This graph shows the total number of publications written about "T-Lymphocytes" by people in this website by year, and whether "T-Lymphocytes" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 12 | 8 | 20 | | 1997 | 20 | 6 | 26 | | 1998 | 21 | 8 | 29 | | 1999 | 19 | 6 | 25 | | 2000 | 22 | 5 | 27 | | 2001 | 23 | 9 | 32 | | 2002 | 20 | 13 | 33 | | 2003 | 20 | 11 | 31 | | 2004 | 23 | 15 | 38 | | 2005 | 28 | 8 | 36 | | 2006 | 22 | 14 | 36 | | 2007 | 17 | 10 | 27 | | 2008 | 18 | 16 | 34 | | 2009 | 23 | 14 | 37 | | 2010 | 16 | 15 | 31 | | 2011 | 11 | 21 | 32 | | 2012 | 15 | 12 | 27 | | 2013 | 33 | 15 | 48 | | 2014 | 21 | 13 | 34 | | 2015 | 21 | 14 | 35 | | 2016 | 20 | 7 | 27 | | 2017 | 19 | 16 | 35 | | 2018 | 23 | 27 | 50 | | 2019 | 24 | 23 | 47 | | 2020 | 25 | 22 | 47 | | 2021 | 24 | 27 | 51 | | 2022 | 10 | 21 | 31 | | 2023 | 4 | 27 | 31 | | 2024 | 12 | 28 | 40 | | 2025 | 24 | 5 | 29 | | 2026 | 5 | 3 | 8 |
To return to the timeline, click here.
Below are the most recent publications written about "T-Lymphocytes" by people in Profiles.
-
Kendirli PK, Erdem S, Kisaarslan AP, Gök V, Kayhan E, Özcan A, Dogan ME, Klein C, Ünal E, Eken A. A novel ELF4 gene variant disrupts T and NK cell function in a patient with immune thrombocytopenia (ITP). Inflamm Res. 2026 May 19; 75(1).
-
Lee J, Chung YM, Silver DJ, Hao Y, Harwood DSL, Ealy A, Serapiglia AM, Curtin L, Benedetti JR, Ballard CAP, Lapsley K, Alvarez-Vazquez A, Goldberg J, Li C, Kaur S, Neal R, Wang SZ, Kay KE, Volovetz J, Hong ES, Fodor R, Jarmula J, Nicosia M, Rubin JB, Swanson KR, Ostrom QT, Panicker N, Kristensen BW, Berens M, Sharifi N, Lathia JD. Androgen loss accelerates brain tumour growth via HPA axis activation. Nature. 2026 May; 653(8116):1184-1195.
-
Eken A, Johnson SA, Erdem S, Hsieh EWY. LCK'ed in: Inborn errors of immunity in LCK reveal how TCR signaling is calibrated. J Exp Med. 2026 May 04; 223(6).
-
Garza B, Calhoun J, Norman PJ, Cline N, Kichula KM, Farias TDJ, Sams S, Boorgula MP, Danhorn T, Haugen BR, French JD. Tumor-infiltrating T Lymphocytes Recognize Thyroid-specific Proteins and Neo-antigens in Follicular Cell-derived Thyroid Cancers. J Clin Endocrinol Metab. 2026 Apr 22; 111(5):e1289-e1301.
-
Kim D, Moon SJ, Han EL, Feng E, Murray AM, Wang J, Liu W, Kong G, June CH, Mitchell MJ. HITE: HIV Inspired Lipid Nanoparticle Platform for CAR T Cell Engineering. Nano Lett. 2026 May 06; 26(17):5668-5679.
-
Carturan A, Angelos MG, Guruprasad P, Patel RP, Pajarillo R, Lee A, Espie D, Zhang Y, Chiang YH, Xie W, Rodriguez JL, Harris J, Devi P, Afolayan-Oloye OI, Xu J, Sussman JH, Elghawy O, Yang A, Barsouk A, Cho JH, Shaw CE, Singh E, Ugwuanyi O, Paruzzo L, Stella F, Liu S, Nason S, Imparato A, Rotolo A, Lemoine J, Barrett DM, Posey A, Rook AH, Pillai V, Bagg A, Pileri SA, Liu D, Tan K, Schuster SJ, Teachey DT, Porazzi P, Ruella M. Harnessing the CD2 axis to broaden and enhance the efficacy of CAR T-cell therapies. Blood. 2026 Apr 16; 147(16):1842-1856.
-
Dreyzin A, Yates B, Shalabi H, Silbert SK, Wang HW, Yuan CM, Hoang CN, Culbert AA, Gava F, Nair MS, Giordani VM, Little L, Foley T, Nussenblatt V, Fry TJ, Stroncek DF, Highfill SL, Shah NN. Ten-year experience of CD22 CAR T cells for children and young adults with B-cell acute lymphoblastic leukemia. Blood Adv. 2026 Mar 10; 10(5):1700-1712.
-
Ang MJY, Metzloff AE, Thatte AS, Mitchell MJ. Lipid nanoparticles for engineering next generation CAR T cell immunotherapy. Nanoscale Horiz. 2026 Jan 05; 11(1):22-36.
-
DeGolier KR, Pham-Danis C, Burciaga SD, Walsh ZH, Brzezinski C, Novak AJ, Leach L, Cimons J, Li W, Zhongyu Z, Dimitrov D, Scott-Browne JP, Kohler ME, Fry TJ. Rational redesign of antigen binding domain improves in vivo efficacy of the CD22-CAR. Mol Ther. 2026 Apr 01; 34(4):2175-2188.
-
Landry LG, Wells KL, Anderson AM, Miller KR, Jones KL, Michels AW, Nakayama M. Quantitative V gene-targeted T cell receptor sequencing as a biomarker in type 1 diabetes. JCI Insight. 2026 Feb 09; 11(3).
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|